-49%

est. 2Y upside i

HealthcareSeries C

Rank

#2653

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

AbogenBio is a clinical-stage biotech with a strong proprietary mRNA platform and multiple INDs in high-growth markets like immuno-oncology and infectious diseases.

Last updated: March 10, 2026

Bull (20%)+200%

Successful Phase 2/3 clinical trial readouts for the KRAS mRNA vaccine and Shingles vaccine lead to accelerated regulatory pathways and lucrative partnerships, driving the valuation to $9.0B (3x current) as the company demonstrates platform validation and a clear path to commercialization in high-value markets.

Base (40%)+33%

Continued progress in early-stage clinical trials for key pipeline assets, including the KRAS mRNA vaccine, but facing slower-than-expected regulatory approvals and intense competition from incumbents. Valuation grows modestly to $4.0B (+33%) as the company secures additional funding rounds, pushing IPO timelines further out.

Bear (40%)-50%

Clinical setbacks or delays for lead candidates, particularly the KRAS mRNA vaccine, coupled with increased competitive pressure from dominant players like Moderna and BioNTech, and ongoing regulatory challenges in China, lead to a down round or a significant decrease in valuation to $1.5B (-50%), severely impacting common stock value due to liquidation preferences.

Est. time to liquidity~3.5 years

Preference Stack Risk

severe

Funding Intensity

38%

Investors have put in $1.13 billion, representing 37.7% of the current $3.0 billion valuation. This means in an exit at or below $3.0 billion, common shareholders (employees) could see significantly reduced or no returns due to liquidation preferences.

Dilution Risk

high

As a clinical-stage biotech, AbogenBio will require substantial additional capital to advance its pipeline through late-stage clinical trials and potential commercialization, which will likely lead to further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for AbogenBio employee shares.

Questions to Ask at the Interview

Strategic questions based on AbogenBio's data — designed to show you've done your homework.

  • 1

    “Given the strong competitive landscape with incumbents like Moderna and BioNTech actively expanding into immuno-oncology, how does AbogenBio plan to differentiate its KRAS mRNA vaccine and secure market share, particularly in global markets beyond China?”

  • 2

    “With multiple IND approvals and a very high capital intensity, what is the company's strategy for managing its cash runway and minimizing dilution for employees in the next 2-3 years, especially considering the need for further clinical development?”

  • 3

    “Considering the $1.13 billion in total funding relative to the $3.0 billion valuation, how does the company communicate the preference stack and potential impact on common stock value to employees, and what is the anticipated timeline for a liquidity event such as an IPO?”

Community

Valuation Sentiment

Our model estimates -49% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.